Microcap Ledger

Tickers · $NMAD

Nomad Power Solutions, Inc. $NMAD

By Microcap Ledger desk · CIK 0001335105

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Pharmaceutical Preparations
Headquarters
Boca Raton, FL
Fiscal year end
December 31
Shares outstanding
16,101,068 [10-Q 2026-08-14]
as of 2026-08-10

Sources: [10-K 2026-03-31]

What the company doesAI summary of filing

Nomad Power Solutions, Inc. (also known as Lixte Biotechnology Holdings, Inc.) is a clinical-stage biopharmaceutical and proton cancer therapy company. The company develops cancer therapies primarily focused on protein phosphatase 2A inhibitors, with its lead compound LB-100 currently in clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and soft tissue sarcoma. The company is also the majority shareholder of Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton therapy linear accelerator for treating various cancers. The company is pre-revenue and has not commenced revenue-generating operations, relying on equity capital to fund operations. [10-K 2026-03-31]

Segments: LB-100 (protein phosphatase 2A inhibitor for cancer therapy), LiGHT System (proton therapy linear accelerator), LB-200 series (histone deacetylase inhibitors, preclinical stage)

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026—−$4.33M −$3.44M$12.67M[10-Q 2026-08-14]
FY ended Dec 2025—−$6.08M −$3.07M$5.11M[10-K 2026-03-31]
FY ended Dec 2024—−$3.59M −$3.16M$1.04M[10-K 2026-03-31]
Quarterly cash burn
−$1.72M
Cash runway Estimate
~22.1 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-012,249,290[10-Q 2024-11-12]
2025-03-142,684,074[10-K 2025-03-24]
2025-04-302,684,074[10-Q 2025-05-12]
2025-08-054,561,363[10-Q 2025-08-07]
2025-11-055,704,200[10-Q 2025-11-12]
2026-03-3111,617,944[10-K 2026-03-31]
2026-05-1212,382,944[10-Q 2026-05-14]
2026-08-1016,101,068[10-Q 2026-08-14]
Shelf registration
S-1 filed 2025-06-18; declared effective 2025-07-15 [S-1 2025-06-18]

Listing status

Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2025-04-188-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-04-18]
2025-02-218-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2025-02-21]
2024-10-238-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2024-10-23]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-07-01Stazzone Petergrant50,000—[4 2026-07-02]
2026-07-01Sawyer Jason Davidgrant40,000—[4 2026-07-02]
2026-07-01Pursglove Geordan Garrettgrant350,000—[4 2026-07-02]
2026-07-01Primus Guy Warrengrant15,000—[4 2026-07-02]
2026-07-01Holloway Michael Andrewgrant15,000—[4 2026-07-02]
2026-07-01Felix Lourdesgrant30,000—[4 2026-07-02]
2026-05-29Porter Stuart Dgrant25,000—[4 2026-06-01]
2026-04-15Pursglove Geordan Garrettgrant350,000—[4 2026-04-17]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.